Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

While Gearing Up To Supply Biosimilars To U.S. And EU Markets, Will Leading Chinese Biotech 3SBio Be M&A Target?

This article was originally published in PharmAsia News

Executive Summary

BEIJING - One of China's leading biopharmaceutical developers, 3SBio, reported solid earnings for the third quarter of 2010, which could help make the firm ripe for a takeover by an international player

You may also be interested in...



3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)

Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.

3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)

Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.

Innovation To Drive Long-Term Survival In China Pharma Market - But What Kind Of Innovation?

BEIJING - For Big Pharma and domestic players competing in China's market, innovation is essential for long-term survival, even as pricing strategies might help grab market share over the shorter term, according to a prominent analyst who monitors China's healthcare sector

Related Content

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel